Sarcoma
Invited discussant abstracts 1398PD, 1399PD and 1400PD
Date
10 Oct 2016Session
SarcomaPresenters
Maud ToulmondeAuthors
M. ToulmondeAuthor affiliations
- Institute Bergonié, 33076 - Bordeaux/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2462 - Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021
Presenter: William Tap
Session: Sarcoma
Resources:
Abstract
Slides
Webcast
1473 - Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
Presenter: Axel Le Cesne
Session: Sarcoma
Resources:
Abstract
Slides
Webcast
2285 - The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment
Presenter: Jean-Yves Blay
Session: Sarcoma
Resources:
Abstract
Slides
Webcast
2559 - Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): a novel therapeutic approach
Presenter: Anastasia Constantinidou
Session: Sarcoma
Resources:
Abstract
1496 - PD1 and PDL1 expression, tumoral microenvironment (TME) characterization and clinical implication in localized osteosarcoma
Presenter: Emanuela Palmerini
Session: Sarcoma
Resources:
Abstract
3060 - Anti-PD1 therapy with nivolumab in sarcoma
Presenter: Luca Paoluzzi
Session: Sarcoma
Resources:
Abstract
1879 - Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS
Presenter: Jean-Yves Blay
Session: Sarcoma
Resources:
Abstract
3135 - Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients
Presenter: Robin Jones
Session: Sarcoma
Resources:
Abstract
Invited discussant abstracts 1401PD and 1402PD
Presenter: Xavier Garcia del Muro
Session: Sarcoma
Resources:
Slides
Webcast
2132 - Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib
Presenter: Nienke Lankheet
Session: Sarcoma
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.